Cathepsin B Inhibitors as Therapeutics for Ebola Infection

Information

  • Research Project
  • 8980049
  • ApplicationId
    8980049
  • Core Project Number
    R43AI120926
  • Full Project Number
    1R43AI120926-01
  • Serial Number
    120926
  • FOA Number
    PA-14-071
  • Sub Project Id
  • Project Start Date
    7/1/2015 - 9 years ago
  • Project End Date
    8/31/2016 - 8 years ago
  • Program Officer Name
    DAVIS, MINDY I.
  • Budget Start Date
    7/1/2015 - 9 years ago
  • Budget End Date
    8/31/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    01
  • Suffix
  • Award Notice Date
    6/15/2015 - 9 years ago
Organizations

Cathepsin B Inhibitors as Therapeutics for Ebola Infection

? DESCRIPTION (provided by applicant): Ebola virus (EBOV) of the filovirus family is an enveloped, single-stranded RNA virus that causes severe hemorrhagic fever in multiple mammals including humans and non-human primates. The recent 2013-2014 outbreak of EBOV in West Africa has resulted in the deaths of nearly 40% of infected patients to date, spreading throughout West Africa and internationally to the United States and Spain via travelers. Therefore, it is essential to understand how this virus invades its hosts and causes disease, to spur approaches to treatment and prevention. Because entry into host cells is the first step in the viral life cycle, this area offers a major target for treatment and prevention. Importantly, ithas been demonstrated that EBOV requires the activity of human Cathepsin B (CatB) for sequential processing of its glycoprotein GP1. The fact that EBOV utilizes this key human protease, CatB, for entry offers an opportunity to develop anti-EBOV inhibitor drugs. We aim to generate potent, specific inhibitors for CatB via exploration of the prime side ?-helical binding pocket that resuts in inhibition of EBOV infection in live cell assays.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    222382
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:222382\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHELIX THERAPEUTICS, LLC
  • Organization Department
  • Organization DUNS
    079291041
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191045504
  • Organization District
    UNITED STATES